Paul Waldman: I just want to highlight what you said there because it's so important, and this is fairly technical. You talked about these Mendelian randomizations, which are abbreviated MR, and similar to that, are genome-wide association studies called GWAS. And those are the evidence put forth by people who are preaching that APOB is a direct driver of cardiovascular disease. He says we need to treat the whole patient, not a biomarker; medicine shouldn't be an exact fine. Waldman: We should give patients numbers in a way that they can understand their hopes and anxieties without coercion.
This week, Paul chats with cardiologist, public health campaigner and author, Aseem Malhotra. They touch on pharmaceuticals, statins, and whether LDL cholesterol is a big deal. They also provide tools to assess your metabolic health and stress levels in an objective manner.
00:09:38 Podcast begins
00:10:38 What sparked Aseem’s interest in the root of disease
00:12:58 Big Pharma’s influence on dietary guidelines